Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK3528885
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK3528885 is an investigational therapeutic vaccine developed by GSK for the treatment of chronic hepatitis B (CHB). It is a viral vector vaccine based on a non-replicating chimpanzee adenovirus (ChAd153) platform, engineered to express multiple hepatitis B virus (HBV) antigens, including the surface antigen (HBsAg), core antigen (HBcAg), and polymerase. The vaccine is designed to elicit a potent and broad T-cell-mediated immune response, specifically targeting CD8+ and CD4+ T-cells to overcome the immune exhaustion characteristic of chronic HBV infection and facilitate the clearance of infected hepatocytes. GSK3528885 is frequently evaluated in clinical trials as part of a heterologous prime-boost regimen, often paired with a Modified Vaccinia Ankara (MVA) vector vaccine (GSK3965193) or in combination with other therapeutic agents like the antisense oligonucleotide bepirovirsen.
- Other names
- HBV viral vector vaccine 8885
02
Targets
HBsAg (Hepatitis B surface antigen)HBc (Hepatitis B virus core protein)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on GSK3528885.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK3528885.